These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1562 related articles for article (PubMed ID: 34092181)

  • 1. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
    Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
    Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
    Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
    Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
    Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
    [No Abstract]   [Full Text] [Related]  

  • 5. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    Lustig Y; Nemet I; Kliker L; Zuckerman N; Yishai R; Alroy-Preis S; Mendelson E; Mandelboim M
    N Engl J Med; 2021 Jun; 384(25):2453-2454. PubMed ID: 33826815
    [No Abstract]   [Full Text] [Related]  

  • 7. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
    Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H
    Front Immunol; 2021; 12():743422. PubMed ID: 34659239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
    Liu Y; Liu J; Xia H; Zhang X; Zou J; Fontes-Garfias CR; Weaver SC; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Jul; 385(5):472-474. PubMed ID: 33979486
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
    Valleriani F; Mancuso E; Vincifori G; Teodori L; Di Marcantonio L; Spedicato M; Leone A; Savini G; Morelli D; Bonfini B; Lorusso A
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
    Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
    Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
    [No Abstract]   [Full Text] [Related]  

  • 16. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
    Bates TA; Leier HC; Lyski ZL; McBride SK; Coulter FJ; Weinstein JB; Goodman JR; Lu Z; Siegel SAR; Sullivan P; Strnad M; Brunton AE; Lee DX; Adey AC; Bimber BN; O'Roak BJ; Curlin ME; Messer WB; Tafesse FG
    Nat Commun; 2021 Aug; 12(1):5135. PubMed ID: 34446720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Activity of BNT162b2-Elicited Serum.
    Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
    [No Abstract]   [Full Text] [Related]  

  • 19. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
    Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
    N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
    [No Abstract]   [Full Text] [Related]  

  • 20. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
    Messali S; Bertelli A; Campisi G; Zani A; Ciccozzi M; Caruso A; Caccuri F
    J Med Virol; 2021 Dec; 93(12):6468-6470. PubMed ID: 34329486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 79.